Bipolar Disorder: Can Competitive Advantage Be Established in a Challenging Market

Countries covered: United States A poorly understood, complex disease that involves a number of neurotransmitters, bipolar disorder presents several challenges for pharmaceutical companies seeking to develop new treatments. While lithium and several antiepileptic and antipsychotic agents are currently used to treat either manic or mixed episodes of BPD, only Eli Lilly's Symbyax and AstraZeneca's Seroquel have received FDA approval for treatment of bipolar depression. The numerous unmet therapeutic needs resulting from the incomplete understanding of BPD create significant opportunities within the competitive BPD market. Get the Answers You Need to Shape Your Strategy Bipolar disorder represents a market with significant opportunity, but few drug companies are actively developing new agents. What obstacles are currently deterring companies from entering the BPD market? What challenges need to be addressed, and what therapeutic needs remain unmet? The treatment of depression associated with BPD has not been as extensively studied as the treatment of either unipolar depression or bipolar mania. What strategies does treatment of bipolar depression rely upon? Which classes of antidepressants appear to be the most effective for treating bipolar depression? Several agents have received specifi c approval for treating BPD; other agents are commonly used off-label. Which agents are most frequently used as off-label treatments for BPD? What competitive advantages, if any, does FDA approval provide? Which companies are specifi cally pursuing FDA approval for their BPD agents? Please note, the PDF e-mail from publisher version of this report is for a global site license.

Additional Information

Scope
BPD background: Symptoms, pathophysiology, and etiology.
Treatment options: Current therapies for the four common types of episodes associated with bipolar I disorder and bipolar II disorder.
Market dynamics: Sales growth statistics for BPD-approved agents versus non-BPD-approved agents; sales and prescriptions of antipsychotics and antiepileptics in the United States.
Emerging therapies: Antipsychotics and sodium- and calcium-channel blockers currently in development, along with novel approaches.
Market outlook: Limitations of current BPD agents; challenges still remaining; and the likelihood that any one agent will dominate the BPD market.

Companies Mentioned in This Spectrum Report

Abbott Laboratories
AstraZeneca
Bristol-Myers Squibb
Dainippon
D-Pharm
Eli Lilly
Forest Laboratories
Gedeon Richter
GlaxoSmithKline
Hoechst Marion Roussel
Janssen
Janssen-Cilag International
Johnson & Johnson
Kyowa Hakko
H. Lundbeck
Marinus Pharmaceuticals
McNeil
Memory Pharmaceuticals
Novartis
Organon
Ortho-McNeil
Otsuka Pharmaceutical
Pfizer
Repligen
Sanofi -Aventis
Shire Pharmaceutical
Solvay Pharmaceuticals
Taisho
Titan Pharmaceuticals
Vanda Pharmaceuticals
Wyeth

More United States Behavioral Health Reports

Mental Health & Substance Abuse Services by First Research, Inc.
Brief Excerpt from Industry Overview Chapter: The US mental health and substance abuse services industry includes about 15,000 establishments (single-location companies and units of multi-location companies) ...

Mental Health & Substance Abuse Clinics in the US - Industry Market Research Report by IBISWorld
Getting better: Expanded coverage and healthcare reform will spur demand for clinics Mental Health & Substance Abuse Clinics in the US Brighter days ahead : Rising appreciation for ...

Family Counseling & Crisis Intervention Services in the US - Industry Risk Rating Report by IBISWorld
This Industry Risk Ratings report from IBISWorld evaluates the inherent risks associated with the Family Counseling & Crisis Intervention Services in the US industry. Industry ...

Mental Health & Substance Abuse Centers in the US - Industry Risk Rating Report by IBISWorld
This Industry Risk Ratings report from IBISWorld evaluates the inherent risks associated with the Mental Health & Substance Abuse Centers in the US industry. Industry ...

Psychologists, Social Workers & Marriage Counselors in the US - Industry Risk Rating Report by IBISWorld
This Industry Risk Ratings report from IBISWorld evaluates the inherent risks associated with the Psychologists, Social Workers & Marriage Counselors in the US industry. Industry ...

See all reports like this >>

More United States Reports

e-Discovery Software Publishing in the US - Industry Market Research Report by IBISWorld
e-Discovery Software Publishing in the US Finding growth : Electronic discovery (more often known as e-discovery) refers to a data search, location and securing process for use ...

D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country Report: The United States of America by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...

Country Report United States January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

Coal - US - a snapshot (2010) by Mintel - Snapshots
Coal in US by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers consumption ...

See all reports like this >>